Novartis has announced a strategic agreement with Synnovation Therapeutics, LLC to acquire SNV4818, an investigational oral therapy designed to treat hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer and potentially other solid tumors. The deal underscores Novartis’ continued investment in precision oncology and next-generation targeted therapies.
SNV4818 is a pan-mutant selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial involving patients with breast cancer and other advanced solid tumors. The therapy is designed to address a well-established driver of disease: mutations in the PIK3CA gene, which are present in approximately 40% of HR+/HER2- breast cancer cases and are often associated with poorer clinical outcomes.
Unlike existing treatments in this class, SNV4818 is engineered to selectively inhibit the mutated form of the PI3Kα enzyme found in cancer cells, while sparing the normal, or wild-type, version of the enzyme in healthy tissue. This targeted approach aims to overcome a longstanding limitation of current PI3Kα inhibitors, which can cause significant side effects due to their lack of selectivity, often leading to treatment discontinuation.
Shreeram Aradhye, President of Development at Novartis, highlighted the potential of this new approach, noting that while PI3Kα mutations are a well-validated target in breast cancer, achieving effective inhibition without compromising tolerability has remained a challenge. He emphasized that SNV4818’s mutant-selective chemistry could enable more precise targeting of tumor biology, potentially improving patient outcomes through better tolerability and sustained therapeutic benefit.
The acquisition also aligns with Novartis’ broader strategy to expand combination treatment options in breast cancer. SNV4818 is expected to complement existing therapies such as CDK inhibitors and endocrine (hormonal) treatments, potentially allowing for earlier and more effective intervention in the disease course.
Preclinical studies of SNV4818 have demonstrated strong activity against common PIK3CA mutations and a clear ability to distinguish between mutant and normal PI3Kα enzymes. Clinical trials are ongoing to further evaluate its safety and efficacy in patients.
With this move, Novartis reinforces its commitment to advancing innovative therapies aimed at improving the quality of life and outcomes for patients with breast cancer and other difficult-to-treat cancers.